Press release
Cancer Profiling Tests Analysis, Top Leaders, Opportunities, Future Scope, Developments and Regional Forecast to 2031 | F. Hoffmann La Roche Ltd, Illumina Inc., QIAGEN, Thermo Fisher Scientific Inc., Abbott
Browse Full Report, visit at https://www.factmr.com/report/358/cancer-profiling-market
The market received major tailwinds in the past, registering an absolute opportunity worth US$ 36 million in 2019, expanding at an annual rate of around 4%. Gains were especially evident in the breast cancer segment, attributed to growing approvals of treatment approaches by regulatory bodies. For instance, in 2019, the Food & Drug Administration approved a supplemental new drug application for palbocicib (IBRANCE) to expand approved indications in women with hormone receptor (HR)-positive and HER2-negative metastatic breast cancer (MBC) in combination with a fulvestrant.
Opportunities abound across the lung cancer segment, with prominent cancer profiling testing kit providers vying for targeted therapies. Players such as AstraZeneca are at the forefront of non-small cell lung cancer therapy (NSCLC). The company specializes in offering tissue-based diagnostics and plasma-based (ctDNA) diagnostics. Its approach targets the epidermal growth factor receptor (EGFR), which occurs in 10-15% of NSCLC patients.
Request a Report Sample to Gain Valuable Insights: https://www.factmr.com/connectus/sample?flag=S&rep_id=358
Key Takeaways from Market Study
By indication, non-small cell lung cancer (NSCLC) is likely to aggrandize impressively through 2031
Fluorescence in-situ hybridization (FISH) instruments to experience high sales
The U.S. to experience heightened growth amid increasing cancer prevalence amongst the population
The U.K. to receive tailwinds amid increasing biological research programs to test diagnostics efficacy
Robust institutional frameworks to accelerate oncology research pivoting cancer profiling expansion across Germany
India to emerge as a heavyweight in the cancer profiling market, attributed to increasing prevalence in the wake of an exponential population upswing
“Increasing prevalence of debilitating cancers across the developing world is prompting governments to bolster advanced cancer diagnostics and treatment research, prompting increased penetration of cancer profiling solution providers across these market. Opportunities are aplenty across India and China, the regions with the world’s highest population base,” remarks a Fact.MR analyst.
For More Detailed Information about Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=358
Competitive Landscape
As per Fact.MR’s analysis, prominent players operating in the global cancer profiling landscape include F. Hoffmann La Roche Ltd., QIAGEN NV, Siemens Healthineers, HTG Molecular Diagnostics Inc., Biogenex, Pacific Biosciences of California Inc., Abbott, Illumina Inc., and Thermo Fisher Scientific Inc.
These aforementioned players rely on collaborations, acquisitions, and introduction on new technologies in cancer profiling tests to acquire a firm footing. For instance, in August 2020, Siemens Healthineers acquired Varian Medical Systems to effectively leverage its cancer treatment business, for a sum of approximately US$ 16.4 billion.
In August 2020, HTG Molecular Diagnostics Inc. announced the release of its EdgeSeq Reveal Version 3.0 equipped with additional applications and software functionalities. The platform is now equipped with the EdgeSeq Pan B-Cell Lymphoma Panel to assess malignancy in cells.
More Valuable Insights
Fact.MR, in its new offering, presents an unbiased analysis of the global cancer profiling market, presenting historical demand data (2016-2020) and forecast statistics for the period of 2021-2031. The study divulges essential insights on the market on the basis of product (instruments and consumables), indication (breast cancer, colorectal cancer, ovarian cancer, melanoma, kidney cancer, lung cancer (including NSCLC), and rare cancers), and end user (hospitals, diagnostic centers, cancer research institutes, and others), across seven major regions (North America, Latin America, Europe, CIS & Russia, Japan, APEJ, and MEA).
Schedule a FREE Consultation Call with Our Analysts/Industry Experts to Find Solution for Your Business at: https://www.factmr.com/connectus/sample?flag=AE&rep_id=358
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. We are headquartered in Dubai, and operate from our sales office in Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Profiling Tests Analysis, Top Leaders, Opportunities, Future Scope, Developments and Regional Forecast to 2031 | F. Hoffmann La Roche Ltd, Illumina Inc., QIAGEN, Thermo Fisher Scientific Inc., Abbott here
News-ID: 2262756 • Views: …
More Releases from Fact.MR
Self-Administered Medication Market Forecast 2025-2035: Market to Reach USD 256. …
The global self-administered medication market is projected to grow from a valuation of US$ 112.5 billion in 2025 to US$ 256.7 billion by the end of 2035. This steady expansion, driven by a compound annual growth rate (CAGR) of 8.6%, reflects a significant shift toward patient-centric healthcare and the rising prevalence of chronic conditions requiring long-term management.
Request for Sample Report | Customize Report | Purchase Full Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=328
Market…
Snacks Market is Growing at USD 569.2 billion in 2025 | Fact.MR Report
The global snacks market is projected to grow from USD 545.2 billion in 2026 to approximately USD 835.4 billion by 2036. This growth reflects a steady compound annual growth rate (CAGR) of 4.3% over the ten-year forecast period. The market is being fundamentally reshaped by the "snackification" of meals, where busy consumers are increasingly replacing traditional breakfast, lunch, and dinner with portable, nutrient-dense snacking options.
Get Access of Report Sample: https://www.factmr.com/connectus/sample?flag=S&rep_id=50
Quick…
Liquid Nutritional Supplement Market Growing from USD 42.0 billion in 2025 to US …
The global liquid Nutritional supplements market is projected to grow from USD 33.25 billion in 2026 to approximately USD 45.10 billion by 2036. This growth represents a compound annual growth rate (CAGR) of 6.1% to 10.2% depending on the specific product segment (e.g., high-growth Ready-to-Drink formulations vs. traditional tonics).
The market is being primarily driven by a "pill fatigue" trend among consumers and an aging global population that increasingly prefers…
FMCG Logistics Market is Expected to Hit USD 190.5 billion by 2036 | Fact.MR Ins …
The global FMCG logistics market is projected to grow from USD 126.9 billion in 2026 to approximately USD 189.5 billion by 2036. This growth reflects a steady compound annual growth rate (CAGR) of 4.1% over the ten-year forecast period.
The market is entering a decade of transformation, shifting from a focus on cost-driven efficiency to automation-led resilience as retailers and brands navigate the complexities of quick-commerce and global supply chain…
More Releases for NSCLC
NSCLC Treatment Market to Reach USD 55.30B by 2035
Non-Small Cell Lung Cancer Treatment Market: Growth Drivers, Innovation, and the Future of Lung Cancer Care
The Non-Small Cell Lung Cancer (NSCLC) Treatment Market is undergoing a profound transformation as advances in diagnostics, targeted therapies, and immuno-oncology redefine how lung cancer is managed globally. NSCLC accounts for nearly 85% of all lung cancer cases, making it the most prevalent and commercially significant segment of the lung cancer therapeutics market.
Historically, NSCLC was…
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
